Since the FDA approval of ipilimumab in 2011, immune checkpoint inhibitors (ICIs) have reshaped the paradigm of cancer treatments. This has been pursued with the development and clinical investigation of combination immunotherapies with multiple ICIs. However, more than 20% of recipients of ICI monotherapy and a higher...
Mohammad Parsapour, Pouya Mahdavi Sharif, Nima Rezaei· Pathology, Research and Prac...· 0 citations
ABSTRACT Background Ataxia telangiectasia (AT) is a life‐threatening multisystem disorder characterized mainly by neurologic manifestations, infections, and malignancy. We aimed to present a comprehensive analysis of demographic, clinical, immunologic, and genetic features and outcomes of patients with AT in Iran. Meth...
Saba Fekrvand, A. Firouzabadi, Pouya Vakilipour et al.· European Journal of Neurolog...· 0 citations
Senescence-associated mitochondrial dysfunction (SAMD) links aging, metabolic reprogramming, and therapy resistance in ovarian cancer. Persistent damage to mitochondrial DNA (mtDNA), impaired mitochondrial quality control, and disrupted mitochondrial fusion and fission dynamics compromise electron transport (ET) and me...
H. Khalili, Banafshe Abadi, Nima Rezaei· European Journal of Pharmaco...· 0 citations
This review compiles in vitro, in vivo, and in silico data on triazole‐ and imidazole‐based VEGFR‐2 inhibitors, providing a basis for understanding trends relevant to the design and development of optimized anti‐angiogenic agents.
Parisa Nikfar, Mina Hosseini, Nima Rezaei et al.· Archiv der Pharmazie· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.